Agency: Cordis | Branch: H2020 | Program: ERA-NET-Cofund | Phase: HCO-11-2015 | Award Amount: 20.88M | Year: 2016
The ERA-NET NEURON Cofund will coordinate and align European and international research funding programmes in the area of brain-related diseases and disorders of the nervous system. Key activity is the implementation of an EC co-funded joint transnational call for research proposals. The mission of NEURON is based on the fact that disorders of the brain are the major cause for impaired quality of life, and they are a heavy burden not only for patients, their families and carers, but also a socioeconomic problem for society. By improving collaboration and by implementing a variety of additional activities (such as further joint transnational calls and support of early-career scientists) NEURON Cofund will decrease fragmentation of research programmes and improve the funding situation for neuroscience researchers thereby strengthening the search for novel therapeutic approaches to fight brain disease; NEURON Cofund will also develop and provide concrete plans for (i) expanding data sharing, (ii) promoting common data elements for the establishment of patient registries, and (iii) involving stakeholders and relevant existing initiatives such as patient organizations. The aforementioned challenges will be addressed in a network of 22 funding organizations across 14 European Member and Associated States and Third countries.
Agency: Cordis | Branch: H2020 | Program: ERA-NET-Cofund | Phase: HCO-12-2015 | Award Amount: 23.81M | Year: 2015
Antibiotic resistance is a global problem. It is considered by the World Health Organization as one of the three greatest threats to human health for the next decades. Enhanced coordination across national boundaries is needed to accelerate the efforts to tackle this grand challenge. Such synergies have been created among 19 countries in Europe and beyond through the EU JPI on Antimicrobial Resistance (JPIAMR). JPIAMR has developed a Strategic Research Agenda (SRA) which defines the strategic and scientific priorities benefiting from co-ordination and co-operation at the European level and mobilised national funds for two joint transnational calls (JTC) 2014 and 2015 based on this. In the ERA-NET Cofund JPI-EC-AMR, an additional 23 million of national funds will be combined with a highly incentivising EC top-up fund to support a new transnational research programme. The aim of this programme is to unravel the complex dynamics of selection and transmission of antimicrobial resistance (AMR) according to the One Health concept. A multidisciplinary approach is necessary to identify and characterise the determinants that contribute to the spread of resistance at genetic, bacterial, animal, human, societal, and environmental levels, in order to provide scientific knowledge to design and evaluate cost-effective strategies that can decrease transmission of AMR in society. JPI-EC-AMR will launch additional JTCs without EC co-funding under the framework of the SRA. and perform additional joint actions in close collaboration with JPIAMR actions. JPI-EC-AMR will provide a better, quantitative understanding of drug-resistant bacteria in animals, foods, and the environment and to what extent they contribute to the burden of antibiotic-resistant infections in humans. Research in this area is crucial in order to provide the robust scientific evidence needed to make informed decisions regarding interventions and policy measures in hospital, community, and agricultural settings.
Agency: Cordis | Branch: H2020 | Program: RIA | Phase: SC5-04-2015 | Award Amount: 6.82M | Year: 2016
ICARUS will develop innovative tools for urban impact assessment in support of air quality and climate change governance in the EU. This will lead to designing and implementing win-win strategies to improve the air quality and reduce the carbon footprint in European cities. An integrated approach will be used for air pollution monitoring and assessment combining ground-based measurements, atmospheric transport and chemical transformation modelling and air pollution indicators derived from satellite, airborne and personal remote sensing. The ICARUS methodology and toolkit will be applied in nine EU cities of variable size, socio-economic condition and history. Technological and non-technological measures and policy options will be analyzed and proposed to the responsible authorities for air pollution and/or climate change at the city level. Based on the advanced monitoring and assessment tools outlined above, a cloud-based solution will be developed to inform citizens of environment-conscious alternatives that may have a positive impact on air quality and carbon footprint and finally on their health and motivate them to adopt alternative behaviours. Agent-based modelling will be used to capture the interactions of population subgroups, industries and service providers in response to the policies considered in the project. Thus, social and cultural factors, socio-economic status (SES) and societal dynamics will be explicitly taken into account to assess overall policy impact. Our findings will be translated into a web-based guidebook for sustainable air pollution and climate change governance in all EU cities. ICARUS will develop a vision of a future green city: a visionary model that will seek to minimize environmental and health impacts. Transition pathways will be drawn that will demonstrate how current cities could be transformed towards cities with close to zero or negative carbon footprint and maximal wellbeing within the next 50 years.
Agency: Cordis | Branch: H2020 | Program: COFUND-EJP | Phase: SC1-PM-05-2016 | Award Amount: 74.06M | Year: 2017
The overarching goal of the European Human Biomonitoring Initiative (HBM4EU) is to generate knowledge to inform the safe management of chemicals and so protect human health. We will use human biomonitoring to understand human exposure to chemicals and resulting health impacts and will communicate with policy makers to ensure that our results are exploited in the design of new chemicals policies and the evaluation of existing measures. Key objectives include: Harmonizing procedures for human biomonitoring across 26 countries, to provide policy makers with comparable data on human internal exposure to chemicals and mixtures of chemicals at EU level; Linking data on internal exposure to chemicals to aggregate external exposure and identifying exposure pathways and upstream sources. Information on exposure pathways is critical to the design of targeted policy measures to reduce exposure; Generating scientific evidence on the causal links between human exposure to chemicals and negative health outcomes; and Adapting chemical risk assessment methodologies to use human biomonitoring data and account for the contribution of multiple external exposure pathways to the total chemical body burden. We will achieve these objectives by harmonizing human biomonitoring initiatives in 26 countries, drawing on existing expertise and building new capacities. By establishing National Hubs in each country to coordinate activities, we will create a robust Human Biomonitoring Platform at European level. This initiative contributes directly to the improvement of health and well-being for all age groups, by investigating how exposure to chemicals affects the health of different groups, such as children, pregnant women, foetuses and workers. We will also investigate how factor such as behavior, lifestyle and socio-economic status influence internal exposure to chemicals across the EU population. This knowledge will support policy action to reduce chemical exposure and protect health.
Agency: Cordis | Branch: H2020 | Program: ERA-NET-Cofund | Phase: NMBP-11-2016 | Award Amount: 15.27M | Year: 2016
Nanomedicine is the application of nanotechnology to medicine and healthcare. The field takes advantage of the physical, chemical and biological properties of materials at the nanometer scale to be used for a better understanding of the biological mechanisms of diseases at the molecular level, leading to new targets for earlier and more precise diagnostics and therapeutics. Nanomedicine, rated among the six most promising Key Enabling Technologies, is one of the most important emerging areas of health research expected to contribute to one of the strategic challenges that Europe has to face in the future: Provide effective and affordable health care and assure the wellbeing of an increasingly aged population. EuroNanoMed III (ENM III) builds on the foundations of ENM I & II, which launched 7 successful joint calls for proposals since 2009, funded 51 transnational research projects involving 269 partners from 25 countries/regions, and allocated 45,5 million to research projects from ENM funding agencies. ENM III consortium, reinforced with 12 new partners from Europe, Canada and Taiwan, is committed to fostering the competiveness of European nanomedicine actors taking into account recent changes in the landscape and new stakeholders and challenges, as identified in the SRIA in nanomedicine. The first joint call for proposals will be co-funded by ENM III partners and the EC. After the co-funded call, three additional joint transnational calls will be organized and strategic activities will be accomplished in collaboration with key initiatives in the field. ENM III actions focus on translatability of project results to clinical and industry needs.
Agency: Cordis | Branch: H2020 | Program: CSA | Phase: SC1-HCO-04-2016 | Award Amount: 2.23M | Year: 2017
EXEDRA, an EXpansion of the European Joint Programming Initiative on Drug Resistance to Antimicrobials, will build on, and further support the structure and activities of JPIAMR to address the two major objectives of HCO-04-2016 topic: extending JPIAMR globally and creating a long-term sustainable structure for future expansion and governance which will coordinate national funding and collaborative actions supporting the implementation of the JPIAMR Strategic Research Agenda (SRA). JPIAMR EXEDRA will be the second Coordinated Support Action (CSA) for this Joint Programming Initiative (JPI) and essentially build on the work of the first CSA (JPIAMR), which ended February 2016. It will provide a strong support structure for the JPIAMR during the forthcoming implementation and expansion phaseby maintaining a continuity between the objectives, tasks and Work Packages of EXEDRA and JPIAMR. Support facilitated by the CSA EXEDRA will ensure that the ethos of joint programming in the area antimicrobial drug resistance becoming embedded within JPIAMR members research and innovation policies and programmes. EXEDRA will have the following work packages: WP1 Management and coordination; WP2 Strategy, governance, and long term sustainability; WP3 Internationalisation and capacity extension; WP4 Alignment with policy and industry; WP5 Research alignment; WP6 Communication, dissemination, and advocacy. EXEDRA will significantly contribute to the delivery of the JPIAMR SRA combined with the JPI-EC-AMR effort and the experience of the JPIAMR members. EXEDRA (and the JPIAMR) will support transnational cooperation to to pool substantial and long-term research funding and serve to complement other initiatives in the AMR area. It will create momentum with the potential to move the frontiers forward and offer new opportunities for industry, new tools for society, and new evidence-based data for policy makers, which will inspire other necessary initiatives.
Agency: Cordis | Branch: H2020 | Program: ERA-NET-Cofund | Phase: ISIB-12f-2015 | Award Amount: 15.59M | Year: 2016
ERA-HDHL is a proposal of ERA-NET Cofund in the field of nutrition and health to support the Joint Programme Initiative Healthy Diet for a Healthy Life (JPI HDHL). Nowadays, there is a high burden of non-communicable diseases due to unhealthy diet and lifestyle patterns. The 24 members of the JPI HDHL are working together to develop means to (1) motivate people to adopt healthier lifestyles including dietary choices and physical activity, (2) develop and produce healthy, high-quality, safe and sustainable foods and (3) prevent diet-related diseases. Between 2012 and 2015, JPI HDHL had implemented 7 JFAs with 40 M funds from national funding. The JPI HDHL is now set for further enhancement in tight coordination with the EC through the ERA-NET Cofund instrument. ERA-HDHL will provide a robust platform for implementing joint funding actions (JFAs) that address the needs identified in the JPI HDHL strategic research agenda and strengthen the research funding activities of JPI HDHL. An EC cofunded call on the identification and validation of biomarkers in nutrition and health will be implemented. For this foreseen action, the member countries of the JPI HDHL have doubled their financial commitment comparing to previous JFA implemented on a similar topic. Moreover, ERA-HDHL will launch at least 3 additional JFAs in line to fulfil the JPI HDHL objectives.
Agency: Cordis | Branch: H2020 | Program: RIA | Phase: PHC-09-2015 | Award Amount: 24.09M | Year: 2015
HIV-1 is responsible for a global pandemic of 35 million people, and continues to spread at a rate of >2 million new infections/year. It is widely acknowledged that a protective vaccine would be the most effective means to reduce HIV-1 spread and ultimately eliminate the pandemic, while a therapeutic vaccine may help mitigate the clinical course of disease and lead to strategies of viral eradication. However despite 30 years of research, we do not have a vaccine capable of protecting from HIV-1 infection or impacting on disease progression. This in part represents the challenge of identifying immunogens and vaccine modalities with reduced risk of failure in late stage development. To overcome this bottleneck some of the most competitive research groups in vaccine discovery from European public institutions and biotechs from 9 EU countries together with top Australian and Canadian groups and US collaborators, have agreed to join forces in EAVI, providing a pool of international expertise at the highest level. EAVI2020 will provide a platform for the discovery and selection of several new, diverse and novel preventive and/or therapeutic vaccine candidates for HIV/AIDS. Emphasis will be placed on early rapid, iterative, small Experimental medicine (EM) human vaccine studies to select and refine the best immunogens, adjuvants, vectors, homologous and heterologous primeboost schedules, and determine the impact of host factors such as gender and genetics. Animal models will be used to complement human studies, and to select novel immunization technologies to be advanced to the clinic. To shift the risk curve in product development we will develop innovative risk prediction methods, specifically designed to reduce the risk associated with late stage preventive or therapeutic vaccine failure, increasing the chance of discovery of an effective vaccine.
Agency: Cordis | Branch: H2020 | Program: ERA-NET-Cofund | Phase: HCO-07-2014 | Award Amount: 30.95M | Year: 2015
Over 12 million people in Europe suffer from neurodegenerative diseases (ND), yet treatments that prevent or stop the progression of neurodegeneration are still lacking. Tackling this grand challenge requires enhanced coordination of national efforts to accelerate discovery. Such synergies have been created among 28 countries in the pilot EU JPI on Neurodegenerative Disease Research (JPND). JPND has a long standing experience in collaborative action with 75 million of additional national funds being successfully mobilized between 2011 and 2014 to support transnational research programs. The JPND Research Strategy is now ripe for further enhancement in tight coordination with the EC through an ERA-Net Cofund instrument JPco-fuND with an unprecedented commitment of 30 million of national funds associated to a highly incentivizing EC top-up fund. Among the most burning questions, three priority topics have emerged through a consultative process between researchers and JPND members in order to unlock several major issues within ND research: the identification of genetic, epigenetic and environmental risk and protective factors, the development and maintenance of longitudinal cohorts, the creation of advanced experimental models. These are key questions of equal priority to increase understanding of ND mechanisms that will be addressed through a common joint transnational call allowing a significant acceleration of the execution of the JPND research strategy. Moreover, to expand the impact of JPco-fuND, JPND will continue to implement other actions without EU co-funding such as aligning national research strategies, making databases more accessible and interoperable, developing enabling capacities such as supportive infrastructure and platforms, capacity building, education and training. These actions are required in parallel to achieve the highest impact for the patients, their carers and for society as whole and address this grand challenge in the coming years.
Agency: Cordis | Branch: H2020 | Program: ERA-NET-Cofund | Phase: SFS-19-2016-2017 | Award Amount: 10.60M | Year: 2016
HDHL-INTIMIC (INtesTInal MICrobiomics) is a proposal for an ERA-NET Cofund in the field of food, nutrition and health to support the Joint Programming Initiative A Healthy Diet for a Healthy Life (JPI HDHL). There is a high burden of non-communicable diseases due to unhealthy diet and lifestyle patterns. The intestine and in particular the intestinal microbiota have an influence on metabolic processes, thereby contributing to the development of lifestyle-related diseases. The 26 members of the JPI HDHL are working together to develop means to (1) motivate people to adopt healthier lifestyles including dietary choices and physical activity, (2) develop and produce healthy, high-quality, safe and sustainable foods and (3) prevent diet-related diseases. Since 2012, JPI HDHL has implemented seven Joint Funding Actions (JFAs) with around 45 M national funding. In addition, the first ERA-NET Cofund under the umbrella of JPI HDHL, ERA-HDHL, has recently started, implementing an EC cofunded call on Biomarkers on Nutrition and Health with a committed budget of around 12 M. Building on these achievements, HDHL-INTIMIC will now further enhance the collaboration between JPI member countries and between the JPI and the EC by providing a platform for implementing further JFAs that address the needs identified in the JPI HDHL Strategic Research Agenda. In particular, a transnational Knowledge Platform on the interrelation of diet, intestinal microbiomics and health will be implemented via an EC cofunded call and an additional JFA. For this, the JPI HDHL members countries have increased their financial commitments comparing to a previous JFA on a similar topic, including also new partners in these activities. Moreover, HDHL-INTIMIC will launch 1-2 other additional JFAs in line to fulfil JPI HDHL objectives.